10-Q: Co-Diagnostics Faces Going Concern, NASDAQ Delisting Risk

Co-Diagnostics reports significant revenue decline and increased operating losses, raising substantial doubt about its ability to continue as a going concern while facing NASDAQ delisting risk.

Summary

• Total revenue for the three months ended June 30, 2025, was $0.2 million, a significant decrease from $2.7 million in the prior year, primarily due to the absence of grant revenue.
• For the six months ended June 30, 2025, total revenue was $0.2 million, down from $3.1 million in the prior year, also driven by lower product and grant revenues.
• The company reported a net loss of $7.7 million for the three months ended June 30, 2025, compared to $7.6 million for the same period in 2024.
• The net loss for the six months ended June 30, 2025, was $15.3 million, an improvement from $16.9 million in the prior year, mainly due to decreased operating expenses.
• Net cash used in operating activities increased to $17.0 million for the six months ended June 30, 2025, from $13.7 million in the prior year.
• The FDA 510(k) application for the Co-Dx PCR COVID-19 Test and platform for over-the-counter (OTC) use was withdrawn due to concerns regarding the shelf-life stability of a test component.
• The company received an additional 180-day grace period from NASDAQ until January 5, 2026, to regain compliance with the $1.00 minimum bid price requirement.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for 12 months from the date the financial statements were issued.

Sentiment

Score: 2

Explanation: The company faces significant financial challenges, including a substantial revenue decline, increased cash burn from operations, and an explicit going concern warning. Operational setbacks like the FDA application withdrawal and NASDAQ delisting risk further compound the negative outlook.

Positives

• Total operating expenses decreased to $8.2 million for the three months ended June 30, 2025, from $10.1 million in the prior year, and to $16.8 million for the six months, from $20.6 million.
• Net loss for the six months ended June 30, 2025, improved to $15.3 million from $16.9 million in the prior year.
• Cash and cash equivalents increased to $11.1 million as of June 30, 2025, from $2.9 million as of December 31, 2024, primarily due to proceeds from maturities of marketable investment securities.
• Net cash provided by investing activities increased to $24.4 million for the six months ended June 30, 2025, from $12.6 million in the prior year.

Negatives

• Total revenue for the three months ended June 30, 2025, decreased by 92.5% to $0.2 million from $2.7 million in the prior year.
• Total revenue for the six months ended June 30, 2025, decreased by 93.5% to $0.2 million from $3.1 million in the prior year.
• Grant revenue was $0 for both the three and six months ended June 30, 2025, compared to $2.5 million and $2.7 million, respectively, in the prior year.
• Net loss for the three months ended June 30, 2025, increased to $7.7 million from $7.6 million in the prior year.
• Net cash used in operating activities increased to $17.0 million for the six months ended June 30, 2025, from $13.7 million in the prior year.
• The FDA 510(k) application for the Co-Dx PCR COVID-19 Test and platform was withdrawn due to shelf-life stability concerns, delaying commercialization.
• The company received a NASDAQ notification for non-compliance with the $1.00 minimum bid price requirement and was granted an additional 180-day grace period.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months, dependent on obtaining additional financing, reducing expenditures, and executing business plans.
• The company did not regain compliance with NASDAQ's $1.00 minimum bid requirement and faces potential delisting if it fails to do so by January 5, 2026, possibly requiring a reverse stock split.
• There is no guarantee that the Co-Dx PCR platform will receive necessary regulatory approvals for commercialization, or that it can be successfully commercialized even if approved.
• The company is a defendant in one class action claim and four derivative actions, as well as three civil actions for breach of contract, with potential material adverse effects if unfavorable outcomes occur.
• The ability to obtain additional financing in equity capital markets is subject to market and economic conditions, company performance, and investor sentiment, with no assurance of favorable terms or availability.
• Any additional equity financing will most likely be dilutive to current stockholders.

Future Outlook

The company plans to submit an enhanced version of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance, following the collection of clinical evaluation data to support the new test's performance. This new submission will also incorporate more recent Co-Dx PCR platform developments to create greater operational and manufacturing efficiencies. Management intends to provide for capital requirements through equity financing, including selling shares under the ATM Agreement, seeking additional grant funding, and implementing operational efficiencies. The company expects to realize material future benefits from certain aspects of new U.S. tax legislation signed on July 4, 2025.

Management Comments

• "Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued."
• "Our ability to obtain additional financing in equity capital markets is subject to several factors, including market and economic conditions, our performance and investor sentiment with respect to us and our industry."
• "There is no guarantee that our Co-Dx PCR platform will receive the necessary regulatory approvals for commercialization, or that, if regulatory approval is received, we will be able to successfully commercialize this platform."
• "We believe our proprietary and patented molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material."

Industry Context

The molecular diagnostics industry is highly competitive and rapidly evolving, with a strong emphasis on regulatory approvals and technological innovation. The decline in grant revenue and overall revenue suggests a significant reduction in demand for COVID-19 related testing, reflecting a broader industry trend as the pandemic's immediate impact wanes. The company's focus on developing a portable, point-of-care PCR platform aligns with a growing market need for accessible diagnostics, but faces stringent regulatory hurdles, as evidenced by the withdrawn FDA application. The company's proprietary Co-Primers technology aims to offer a competitive advantage through enhanced specificity and lower costs, potentially disrupting traditional PCR testing models.

Corporate Governance

Legal Proceedings

• The company is a defendant in one class action claim and four derivative actions alleging that it promulgated false and misleading press releases to improperly benefit officers and directors by increasing stock price.
• The company is also a party to three civil actions (two in the US and one in the United Kingdom) based on breach of contract claims.
• The company believes these lawsuits are without merit and intends to defend them vigorously, but an unfavorable outcome could have a material adverse effect on its results of operations.

Related Party Transactions

• The company has a services agreement with CoSara Diagnostics Pvt Ltd, its joint venture in India, for research and development consulting and support services. Expenses related to this agreement increased to $422,467 for the six months ended June 30, 2025, from $179,965 in the prior year.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential equity financing, potential reverse stock split, and ongoing net losses. The NASDAQ delisting risk could negatively impact stock liquidity and price. The going concern warning indicates substantial financial uncertainty.
• **Employees**: Potential impact from operational efficiencies and cost reductions, though stock-based compensation expense has decreased.
• **Customers**: Delays in the commercialization of the Co-Dx PCR platform due to regulatory setbacks could affect the availability of new diagnostic products.
• **Creditors**: Increased financial risk due to the company's going concern warning and continued operating losses, which could affect its ability to meet obligations.

Next Steps

• Submit an enhanced version of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance after collecting clinical evaluation data.
• Incorporate more recent Co-Dx PCR platform developments into the COVID-19 test to create greater operational and manufacturing efficiencies.
• Seek additional equity financing, including through the ATM Agreement, and grant funding to meet capital requirements.
• Implement operational efficiencies to manage expenditures and improve cash flow.
• Potentially effect a reverse stock split, if necessary, to regain compliance with NASDAQ's $1.00 minimum bid price requirement by January 5, 2026.

Key Dates

Recommendation

The company is in a precarious financial position, evidenced by a substantial decline in revenue, increased cash burn from operations, and an explicit "going concern" warning. The withdrawal of a key FDA application for its flagship new product (Co-Dx PCR platform) signals significant delays and uncertainty in its commercialization strategy. Furthermore, the company faces NASDAQ delisting risk due to its low share price. While operating expenses were reduced, the overall financial health and future prospects are severely challenged, making it a high-risk investment with significant downside potential.

Keywords

Molecular Diagnostics, PCR Testing, COVID-19, Co-Dx PCR Platform, FDA Regulatory, NASDAQ Compliance, Going Concern, Financial Results, Biotechnology, Diagnostic Equipment